Enzo Biochem, Inc. (NYSE:ENZ) today reported results for the fiscal second quarter and six months ended January 31, 2013.
Jury declares Life Technologies infringed Enzo Biochem patents and awards Enzo $48.6 million
Company Reports Progress on Technology Platforms; Anticipates New Lab-Developed Tests Aimed at Women’s Health Market;
Superstorm Sandy Aftermath Interrupts Clinical Labs Top-Line Growth.
